In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and ...

The latest approval allows Calquence use with bendamustine and rituximab for adults with newly diagnosed mantle cell lymphoma who are not eligible to undergo hematopoietic stem cell transplantation.

AstraZeneca's BTK inhibitor Calquence has become the first drug in the class to be approved by the US FDA as a treatment for adult patients with previously untreated mantle cell lymphoma (MCL ...

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced a collaboration with BeiGene Ltd., a global oncology company that intends to change its name ...